Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2021 16:30 ET | Source: Arvinas Inc.

Arvinas to Present at the UBS Global Healthcare Virtual Conference

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
May 04, 2021 14:52 ET | Source: Arvinas Inc.

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
May 04, 2021 07:00 ET | Source: Arvinas Inc.

Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...
April 05, 2021 16:30 ET | Source: Arvinas Inc.

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
March 10, 2021 16:30 ET | Source: Arvinas Inc.

Arvinas to Participate in Upcoming Virtual Investor Conferences

NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
March 01, 2021 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
February 08, 2021 16:30 ET | Source: Arvinas Inc.

Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
December 28, 2020 16:30 ET | Source: Arvinas Inc.

Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
December 15, 2020 20:35 ET | Source: Arvinas Inc.

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock

NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
December 14, 2020 16:06 ET | Source: Arvinas Inc.

Arvinas, Inc. Announces Proposed Offering of Common Stock

NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...